Amsterdam, 5 February 2007 Elsevier will launch Biotechnology, the Journal, as the official publication of the European Federation of Biotechnology (EFB) in September 2007. Biotechnology, the Journal will be a cross-disciplinary research and review journal aimed at an audience of academic and commercial bioscientists who are interested not only in science but also in its translation and use. The bi-monthly journal will be a platform for peer-reviewed articles and editorial comments related to biotechnology.
Editor-in-Chief of the journal will be John Hodgson who was Editor of Trends in Biotechnology and Senior Editor of Nature Biotechnology. Hodgson is one of the founders of the biotech consultancy firm, Critical I. According to Hodgson, Biotechnology, the Journal will have a global reach in content and subscription base. "It is important for the credibility of Biotechnology, the Journal that it publishes the best in science and reflects technical and political discussion in an entirely international context. The journal will be inclusive, reaching eastward and westward, seeking the excitement and opportunity in the sciences, technologies and businesses behind biotechnology."
The launch of this exciting journal is planned to coincide with the start of ECB13, The European Congress on Biotechnology, which will be held from September 16th 19th in Barcelona, Spain. EFB Secretary General Christian Suojanen comments, "We are extremely pleased to be able to launch the journal with both John Hodgson and Elsevier as partners. Biotechnology, the Journal, will seek to reflect the EFB's recognition that the boundaries of science and commerce do not stop at the borders of the European Union, and that it is vital that Biotechnology, the Journal provides the global context that our members need. We firmly believe that the journal will be a success and thus aid in serving both our members and the life sciences community as a whole."